Disease · MONDO_0004846

placental abruption

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. placental abruption. Diseases, record MONDO_0004846. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004846

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: placental abruption; Open Targets
Open Targets ID: MONDO_0004846; Open Targets
Other names: Abruptio placentae, premature separation of placenta, abruptio placentae, placental abruption (disease), premature separation of placenta; Open Targets
Disease Ontology: DOID:9667; Disease Ontology
MeSH: D000037; MeSH
NCI Thesaurus: C26685; NCI Thesaurus
Highest stage of its drugs: Unknown, for 4 of its 4 drugs, from ClinicalTrials.gov; Open Targets

Drugs4

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
DALTEPARIN SODIUM	CHEMBL1201460	Oligosaccharide	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
ENOXAPARIN	CHEMBL1201685	Oligosaccharide	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
MAGNESIUM SULFATE	CHEMBL3989857	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
TRANEXAMIC ACID	CHEMBL877	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets2

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PLG	Plasminogen	1	Plasminogen inhibitor	Unknown	https://conductscience.org/library/genes/5340	Drugs and targets
SERPINC1	Antithrombin-III	1	Antithrombin-III activator	Unknown	https://conductscience.org/library/genes/462	Drugs and targets

Trials3

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00186069	Magnesium Sulfate vs Placebo for Placental Abruption	Not applicable	30	2017-04-20	Abruptio Placentae	MAGNESIUM SULFATE	Its record names the disease	ClinicalTrials.gov
NCT01068795	Dose Adjusting Enoxaparin Thromboprophylaxis Dosage According to Anti-factor Xa Plasma Levels Improve Pregnancy Outcome	Not applicable	144		Fetal Demise, Fetal Growth Restriction, Preeclampsia, Abruptio Placentae, Thromboembolism	DALTEPARIN SODIUM, ENOXAPARIN	Its record names the disease	ClinicalTrials.gov
NCT05840471	Tranexamic Acid as an Intervention in Abruptio Placenta	Not applicable	116		Vaginal Bleeding, Prolonged Pregnancy	TRANEXAMIC ACID	Open Targets' reading of its record	ClinicalTrials.gov

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Magnesium Sulfate vs Normal Saline: Undelivered With Resolution of Vaginal Bleeding and Contractions in First 48 Hours	12 of 15	10 of 15	30	NCT00186069	Trial comparisons
Magnesium Sulfate vs Normal Saline: serious adverse events	0 of 15	0 of 15	30	NCT00186069	Trial comparisons

Papers from its trials3

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
33779986	DERIVED	1	PubMed
27440463	DERIVED	1	PubMed
26871905	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0004846

GET https://conductscience.org/api/diseases/v1/MONDO_0004846/drugs

API reference For AI assistants